End-of-day quote
Other stock markets
|
||
- | - |
03-22 | HLB Life Science to Raise 148.5 Billion Won via Shares Issuance; Shares Decline 8% | MT |
03-21 | HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 99.59B 72.8M 0 5.81B | Sales 2023 | 97.99B 71.63M 0 5.72B | Capitalization | 1,166B 852M 0 68.03B |
---|---|---|---|---|---|
Net income 2022 | -54.28B -39.68M - -3.17B | Net income 2023 | -5.98B -4.37M - -349M | EV / Sales 2022 | 11 x |
Net Debt 2022 | 16.03B 11.72M 0 936M | Net Debt 2023 | 87.72B 64.12M 0 5.12B | EV / Sales 2023 | 12.8 x |
P/E ratio 2022 |
-18.7
x | P/E ratio 2023 |
-197
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.8% |
Managers | Title | Age | Since |
---|---|---|---|
Sang-Woo Nam
CEO | Chief Executive Officer | 66 | - |
Yang-Gon Jin
CEO | Chief Executive Officer | 58 | 10/12/15 |
Ki-Hwan Kim
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yang-Gon Jin
CEO | Chief Executive Officer | 58 | 10/12/15 |
Sang-Woo Nam
CEO | Chief Executive Officer | 66 | - |
Yoon-Gi Baek
BRD | Director/Board Member | 61 | - |
1st Jan change | Capi. | |
---|---|---|
+20.94% | 72.78B | |
-1.26% | 24.24B | |
+5.13% | 8.59B | |
+8.25% | 8.38B | |
-19.42% | 8.09B | |
+5.56% | 4.81B | |
+16.83% | 4.32B | |
-1.83% | 4.05B | |
-1.65% | 3.93B |